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Background: The societal, clinical and economic burden imposed by the complications of chronic hepatitis C virus
(HCV) infection - including cirrhosis and hepatocellular carcinoma (HCC) - is expected to increase over the coming
decades. However, new therapies may improve sustained virological response (SVR) rates and shorten treatment duration.
This study aimed to estimate the future burden of HCV-related disease in England if current management strategies
remain the same and the impact of increasing diagnosis and treatment of HCV as new therapies become available.
Methods: A previously published model was adapted for England using published literature and government reports,
and validated through an iterative process of three meetings of HCV experts. The impact of increasing diagnosis and
treatment of HCV as new therapies become available was modelled and compared to the base-case scenario of continuing
current management strategies. To assess the ‘best case’ clinical benefit of new therapies, the number of patients treated
was increased by a total of 115% by 2018.
Results: In the base-case scenario, total viraemic (HCV RNA-positive) cases of HCV in England will decrease from 144,000 in
2013 to 76,300 in 2030. However, due to the slow progression of chronic HCV, the number of individuals with cirrhosis,
decompensated cirrhosis and HCC will continue to increase over this period. The model suggests that the ‘best case’
substantially reduces HCV-related hepatic disease and HCV-related liver mortality by 2020 compared to the base-case
scenario. The number of HCV-related HCC cases would decrease 50% by 2020 and the number progressing from infection
to decompensated cirrhosis would decline by 65%. Therefore, compared to projections of current practices, increasing
treatment numbers by 115% by 2018 would reduce HCV-related mortality by 50% by 2020.
Conclusions: This analysis suggests that with current treatment practices the number of patients developing
HCV-related cirrhosis, decompensated cirrhosis and HCC will increase substantially, with HCV-related liver deaths likely
to double by 2030. However, increasing diagnosis and treatment rates could optimise the reduction in the burden of
disease produced by the new therapies, potentially halving HCV-related liver mortality and HCV-related HCC by 2020.
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Chronic Hepatitis C Virus (HCV) infection can induce
hepatic inflammation, which potentially results in progres-
sive fibrosis leading to cirrhosis [1], and hepatocellular
carcinoma (HCC) [2]. These complications typically
develop slowly: untreated, approximately 10% of people
develop cirrhosis within 10 years when infected as young
adults [3], increasing to about 33% within 20 years [1].
HCV-related complications are increasingly common. For
example, hospital admissions in England from HCV-related
end-stage liver disease (ESLD) and HCC rose approximately
four-fold from 574 in 1998 to 2266 in 2012 [4]. Deaths from
HCV-related ESLD and HCC increased from 89 to 326
between 1996 and 2012 [4]. The number of people living
with HCV-related decompensated cirrhosis or HCC in
England is projected to increase about seven-fold from 590
in 1995 to 4210 in 2020 [4]. Therefore, the societal, clinical
and economic burdens imposed by untreated HCV are
expected to continue to rise in coming years as more
patients progress to advanced liver disease.
Antiviral treatment of chronic HCV aims to produce
a sustained virological response (SVR), defined as
undetectable levels of HCV RNA 12 or 24 weeks after
treatment. SVR is associated with reduced all-cause
[5] and liver-related mortality [5,6], and HCC rates
[7]. Dual therapy with pegylated interferon (peg-IFN)
and ribavirin produces SVR in approximately 80% of
genotype 2 and 3 infections and 40-50% for genotype 1
[8,9]. Adding either boceprevir or telaprevir - directly
acting antivirals (DAAs) – to dual therapy improves
the overall SVR for genotype 1 by at least 20-25% in
treatment-naïve patients [9].
Against this background, new DAAs raise the prospect
of improved SVR rates, fewer adverse events and shorter
treatment regimens [10-12]. Indeed, an peg-IFN-free,
pan-genotypic and all-oral regimen appears to be a realistic
possibility [12]. However, new therapies may not ease
the burden of disease unless more people with HCV
are detected and treated. Currently, several barriers
hinder optimal care, including: low diagnosis rates; the
asymptomatic nature of chronic HCV before complications
emerge; social stigma; failure to refer to specialist services;
comorbidities; patient concerns about side effects; and
suboptimal adherence to treatment [13-19]. Treatment rates
among certain hard-to-reach patients, such as injecting drug
users (IDUs) are particularly poor [20].
This analysis projects the burden of disease in England
associated with current HCV management strategies
until 2030 and models the impact of improved diagnosis
and treatment as new therapies become available.
Methods
The model, constructed by the Center for Disease
Analysis (Colorado, USA), has been described in moredetail elsewhere [21]. The model (Microsoft Excel)
tracks chronic HCV progression between 1950 and
2030 by five-year age and gender cohorts, and by
liver-disease stage. Newly infected patients can enter
the model at any year, progress through the disease
stages based on published transition probabilities [22],
and exit the model on: spontaneous clearance of HCV;
achieving SVR; or death (all-cause or HCV-related).
Historical inputs collected from published literature and
reports published by the English government were used to
populate and calibrate the model. For example, the model
has been validated using data from the Office for National
Statistics (ONS) and Public Health England (PHE)
[4,23,24]. Between 1998 and 2012 the model correlates
closely with reported hospital admission data for ESLD
and HCC [4], but provides a more conservative estimate
of each . The model does not distinguish previously
treated patients and naïve patients. However, average SVR
rates used in the model encompass previously treated
patients, naïve patients and patients treated at advanced
stages of disease (F2-F4).
The base-case scenario modelled continuing the
current management strategy on HCV-related disease, in
particular HCC. The base case was compared against a
model of increasing diagnosis and treatment rates as new
therapies become available.
English population data
English population estimates were calculated as a percent
of the total UK population, obtained as 5-year age and sex
cohorts based on the United Nations (UN) population
database [25]. The UN database combines reliable local
data sources and contained estimates for 1950 to 2100 in
a format consistent with the model (i.e. annual 5-year age
and gender cohorts). A limitation of this approach was the
need to estimate the English population from the total UK
population figures. The percentage of the UK population
residing in England in 1991, 2001 and 2011, was obtained
from the ONS and was used to estimate the English
population [26].
Characteristics of the HCV population
PHE, formerly the Health Protection Agency (HPA),
uses a Bayesian model to produce annual estimates of
HCV prevalence in England and Wales [27]. A published
evidence synthesis estimated the excess risk among ethnic
minorities to generate a more robust calculation of HCV
prevalence, based on the presence of antibodies, in England:
0.54% (95% confidence interval [CI]: 0.4%-0.75%) among
the English population over 15 years of age in 2005 [27].
This is equivalent to 0.4% (95% CI: 0.3%-0.6%) of the total
population, including people less than 15 years of age, in
England. Figure 1 shows the HCV prevalence in England in
2005 stratified by age and gender.
Figure 1 The age and gender distribution of HCV in England in 2005 [27].
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(defined as patients who test positive for HCV RNA).
Antibodies indicate previous HCV exposure, not necessar-
ily current infection. Therefore, limiting the model to
individuals positive for HCV RNA ensures that the model
includes only current infections. A rate of 68.7% was used
[28] to calculate the proportion of people with antibodies
to HCV that are also RNA positive. This corresponded to
151,600 (95% CI: 105,100–196,500) viraemic cases in 2005
equivalent to a prevalence of 0.3% (95% CI: 0.2%-0.4%) of
the English population. HCV genotypes 1 and 3 account
for 45% and 46% of infections in England respectively,
according to data collected by 18 sentinel centres between
2007 and 2010 [28]. Table 1 shows the full genotype
distribution.
The annual number of new cases in England peaked in
1990 due to infections associated with blood products,
then decreased after the introduction of blood screening
[29]. The model also included a second peak in 2000
to reflect self-reported needle sharing between 1991
and 2011 [30]. IDU accounted for 90% of laboratory
confirmed HCV cases between 1996 and 2012 [4].
The remaining risk factors reported by diagnostic
laboratories in England during this period were: blood
transfusion or receiving a blood product (2% of
laboratory confirmed HCV cases); sexual exposure
(2%); renal failure (0.4%); vertical transmission from
mother to child; household (0.2%); occupational
(0.2%); and other (4.9%) [4].Table 1 Distribution of HCV genotypes 1–4 in England by
percentage [28]
Genotypes 1a 1 other 2 3a 3 other Other
Distribution 23.0% 21.7% 5.7% 33.4% 12.5% 3.9%HCV-related morbidity and mortality
The model accounts for mortality in the general HCV
population and a high-risk subpopulation. Mortality
in the high-risk population may be higher than in the
background population because of causes unrelated to
HCV (e.g. overdoses and accidents). Active IDUs are
a high-risk population and, therefore, an increased
mortality rate was applied to ensure that the model
does not overestimate the burden of disease. Background
mortality was estimated using a database hosted by the
Max Planck Institute for Demographic Research [31]. We
assumed that the peak IDU occurs between the ages of 15
and 44 years. Therefore, increased mortality among active
IDUs was estimated for individuals between 15 and
44 years of age [32-37].
Diagnosis inputs for the base-case scenario
HCV notification reports from 1992–2010 (n = 8,147)
[38] were adjusted to account for mortality and for
patients who were cured (i.e. no detectable HCV RNA
after antiviral treatment), so that only individuals with
current chronic infection remained. The number of
cured patients was calculated by multiplying the number
of treated patients each year by the average SVR. Based
on these figures, an estimated 67,200 individuals had been
identified living with an antibody-based HCV diagnosis in
2010. Adjusting this value using a viraemic rate of 68.7%,
an estimated 46,200 individuals had been identified with
RNA-confirmed HCV in 2010. Each year, an estimated
5600 individuals are newly diagnosed with chronic
HCV. SVR inputs for the base-case were set at 70%
for genotypes 1–3 and 48% for genotype 4 in 2013 (Table 2).
The average SVR for genotype 1 took into consider-
ation treatment with protease inhibitors (ie boceprevir
and telaprevir).
Table 2 Inputs for the scenario testing the impact of
increasing diagnosis and treatment of HCV
Inputs 2013 (Base) 2014 2016 2018 and after
SVR G1 70% 80% 95% 95%
SVR G2 70% 85% 95% 95%
SVR G3 70% 70% 80% 90%
SVR G4 48% 80% 95% 95%
Age 15 - 64 15 - 64 15 - 69 15 - 74
Eligibility 60% 60% - 80% 80% 95%
Treated 5430 8150 [F2] 10190 [F2] 11710 [F1]
Diagnosed 5600 8400 13430 13430
Age 15 - 64 15 - 69 15 - 74 15 - 74
Cramp et al. BMC Gastroenterology 2014, 14:137 Page 4 of 10
http://www.biomedcentral.com/1471-230X/14/137Treatment numbers for the base-case scenario and future
increases in SVR
The model estimates that 5,430 HCV patients were
treated in England during 2010. This was based on the
number of standard units of peg-IFN sold between
2006 and 2011, with an estimated 26,670 patients
treated in this period (IMS Health Incorporated; Danbury,
Connecticut). This estimate is in line with those of PHE,
which estimates that a total of 27,500 patients were
treated between 2006 and 2011 [4]. The English genotype
distribution was used to estimate the average number
of weeks of treatment and, therefore, the number of
units of peg-IFN used per patient, assuming 80%
adherence. The base-case scenario assumed that the
diagnosis rate, treatment rate and SVR remained
constant from 2013 to 2030.
Once the base case was developed, the model was used
to analyse alternative inputs for the number of patients
treated, eligibility, age-related treatment restrictions, SVR
by genotype (G1, G2, G3, G4), and the total number of
newly diagnosed HCV cases at different times. This
modelled the impact of increasing rates of diagnosis and
treatment of HCV as new DAAs become available.
The model examined the impact of future therapies
becoming available in four waves:
 In 2014, new DAAs (e.g. an NS5B inhibitor) become
available that are combined with peg-IFN and ribavirin
for genotypes 1, 3 and 4. The model for genotype 2
assumed the new DAA is combined with ribavirin only.
 In 2016, further new DAAs are combined with
ribavirin for genotypes 1–4.
 In 2018, ribavirin-free all-oral combinations of
DAAs will be available.
 In 2020, third-generation DAA combinations will
become available.
The model assumed that uptake of new therapies was
immediate. To reflect the increased efficacy of newtherapies, the average SVR was modified for each wave
of new therapies (Table 2).
Increasing diagnosis and treatment of HCV
The model estimated the impact of increasing the number
of patients that are treated with new therapies on
HCV-related morbidity and mortality. To estimate the
‘best case’ of producing an optimal impact with new
therapies on the burden of disease, increases in the
number of treated patients were required. For the
purposes of this analysis, the number of patients
treated was modelled to increase from 5,430 in 2013
to 8,150 in 2014. The number of patients treated then
increased to 10,190 in 2016, and 11,710 in 2018
(Table 2). This increase in treatment was selected to
accomplish a substantial impact of new therapies on
the burden of HCV infection. The increase in treated
patients was initially modelled in those with F2 or
higher fibrosis, before the treated cohort included F1
or higher from 2018 to provide sufficient numbers of
patients to be treated. In the model, eligibility refers
to the number of patients without contraindications who
are willing to accept treatment. New therapies were
assumed to increase eligibility for treatment, increasing
from 60% in 2013 to 95% in 2018. In addition, the upper
age-limit for treatment increased from 69 years old to
74 years old in 2016 (Table 2). To allow for increases in
treatment, the model required that the number of patients
newly diagnosed increased from 5,600 in 2013 to 8,400 in
2014 and to 13,430 in 2016 and beyond (Table 2).
Sensitivity analyses
Sensitivity analyses and Monte Carlo simulations were
performed using Crystal Ball, an Excel add-in by Oracle, to
quantify the impact of uncertainties on modelled outcomes.
Under Monte Carlo simulation, uncertain variables are
represented as probability distributions and model outputs
are recalculated 1,000 times to estimate a range of possible
outcomes. Each recalculation uses a new randomly selected
set of values from the input probability distributions and
the likelihood of each outcome is recorded to generate 95%
uncertainty intervals (95% UI). Beta-PERT distributions
were used for all uncertain variables. Additionally, the
impact of variations in the assumptions made in the ‘best
case’ scenario (including the number of treated and newly
diagnosed patients, and the segment of the population
treated) on HCC cases and the number of liver-related
deaths by 2020 was measured.
Results
Base case
The model estimated that there were 144,000 (95% UI:
103,000-174,000) viraemic cases of HCV in England in
2013 (Figure 2A). The age distribution in 2013 is shown
Figure 2 Outputs from the base case. The number of viraemic cases of HCV in England from 1950 to 2030 (A) and the age distribution of
viraemic cases in England in 2013 (B).
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in 2013 are shown in Table 3.
Peak viraemic prevalence of chronic HCV infection
was reached in 2007 with 153,000 infected individuals.
Since then, the model suggested a decline in overall
prevalence reaching an estimated 76,300 in 2030 (Table 4).
Due to the lag between infection and the onset of
HCV-related hepatic complications, the number of
cases of compensated cirrhosis is projected to peak in
2029 at 14,800, increasing from 9,500 in 2013 (Table 4).
The population with decompensated cirrhosis is estimated
to increase from 860 in 2013 and peak in 2029 at 1400
cases. The number of individuals with HCV-related HCC
is projected to increase from 410 in 2013 to 880 in 2030
(Table 4). Unless current practices of care in England
change, the model forecasts that liver-related mortality
will increase by 90% to 740 by 2030 (Table 4).
The impact in 2020 of increasing diagnosis and treatment
of HCV
Table 5 compares the impact of increasing diagnosis and
treatment of HCV as new therapies become available
compared to continuing with the current strategy. In the
latter case, the model predicts a total of 122,000
viraemic cases of HCV in 2020. Improving diagnostic
and treatment rates by a total of 140% and 115% in 2018
respectively, would reduce the number of cases by 30%
to 89,400 (Figure 3A).
Similarly, by increasing diagnosis and treatment, the
number of HCV-related fibrosis cases in 2020 would
decrease by 20% compared to the base case from
107,000 to 83,500 (Figure 3B). The number of patients
with HCV-related cirrhosis and decompensated cirrhosis
in 2020 would also decrease compared to base case,
declining from 12,600 to 4,850 cases (60% reduction)
and from 1,140 to 410 cases (65% reduction) respect-
ively (Figure 3C and D). Meanwhile, the number of
HCV-related HCC cases would decline from 640 to310, a 50% reduction (Figure 3E). Finally, liver-related
deaths caused by HCV would decrease by 50% from
570 to 280 cases in 2020 (Figure 3F).
Sensitivity analyses
Monte Carlo analysis identified the range around the
prevalence estimate as the largest driver of uncertainty
in the model, accounting for 95% of explained variability.
The results of the sensitivity analyses are shown in Table 6.
Changes in the number of treated patients (from 12,000
annually to 3,000 annually) had the largest impact on
HCC cases and HCV liver-related deaths in 2020. The dis-
ease state of treated patients (treating all ≥ F1 patients)
and the age of the treated patients considered eligible for
treatment (limiting to patients ≤69 years) showed the next
largest impact on HCC cases and HCV liver-related
deaths in 2020.
Discussion
This analysis predicts that if current HCV management
in England remains the same between 2013 and 2030,
the number of patients who will develop cirrhosis due to
HCV will increase from 9,500 to 13,700 and cases of
HCV-related decompensated cirrhosis will rise from 860
to 1,280. On the other hand, the model suggests that
treating more patients with HCV will reduce the
number of cases of HCV-related advanced hepatic
diseases – including deaths from HCC and liver-related
mortality – in England.
Improved referral and new treatments may increase
the number of patients who can be treated. Optimising
the clinical impact will require increases in treatment
numbers of 50% across genotypes 1–4, from 5,430 to
8,150 in 2014 and by an additional 25% in 2016 to
10,190. A final increase of 15% in 2018 would bring the
total to 11,710, a value that needs to be sustained until
2020 to optimise the clinical impact. The study planning
and review meetings reached a consensus that the initial
Table 3 Summary of the historical inputs and estimates for the HCV population in the base case
Inputs Historical (confidence interval) Year 2013 (uncertainty interval)
HCV infected cases 220720 (153000–286000) 2005
Antibody HCV prevalence 0.4% (0.3% - 0.6%)
Total viraemic cases 151640 (105110–196480) 2005 144000 (103000–174000)
Viraemic prevalence 0.3% (0.2% - 0.4%) 0.3%
Viraemic rate 68.7% 68.7%
HCV diagnosed (Viraemic) 46200 2010 49730
Viraemic diagnosis rate 30.4% 34.5%
Annual newly diagnosed 5600 2010 5600
New infections 3980
New infection rate (per 100 K) 7
Treated
Number treated 5430 2011 5430
Annual treatment rate 3.6% 3.8%
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higher stage of fibrosis before being expanded to include
F1 in 2018.
PHE modelled the impact on liver disease and HCC of
increasing treatment of HCV with peg-IFN and ribavirin.
Based on increasing the number of patients treated by
100%, PHE estimated that an additional 190 cases of
ESLD and HCC could be prevented over ten years. PHE
also calculated that from 2006 to 2011 27,500 HCV
patients in England were probably treated based on
purchasing and prescribing data for peg-IFN, equivalent
to approximately 20% of the prevalent pool [4]. We
calculated that 5430 HCV patients were treated annually
in England using peg-IFN, which is in line with the PHE
estimates [4]. However, the PHE assumed that peg-IFN
and ribavirin would be the future standard of care,
while this analysis also measured the use of the protease
inhibitors boceprevir and telaprevir in genotype 1. The
PHE report noted that if new therapies are easier for
patients to tolerate then increasing treatment rates will
become more feasible [4]. Therefore, our analysis probably
offers a more realistic indication of potential health gains
than the PHE estimates.
Reducing premature mortality from liver disease and
cancer are important outcome measures for the National
Health Service (NHS) [39]. The analysis shows thatTable 4 Outcomes of the base-case scenario at 2013 and 203
Base-case
outcomes (year)




2013 144000 133000 9500
(103000–174000) (95200–162000) (4000–16600)
2030 76300 59500 13700
(35300 – 106000) (26500 – 89400) (6370 – 20900)increasing treatment numbers by 50% in 2014 and by a
further 44% in 2018 is likely to reduce liver-related
mortality among HCV-infected patients by 50% in
2020 compared to the projections of current practices.
This scenario depends on increases in SVR and diagnosis,
and assumes that patients with advanced fibrosis (≥F2) are
treated before those with less advanced fibrosis. The
number of HCV-related HCC cases would also decrease
by 50% in 2020. In addition, in 2020 the number of
patients progressing to decompensated cirrhosis
would decrease by 65%. The model predicts that the
total number of HCV RNA-positive patients will decline
by 30% compared to the projected impact of current
treatment strategies.
Sensitivity analyses examined the impact of a range of
widely variable assumptions on HCV-related morbidity
and mortality compared to the scenario that modelled
increased diagnosis and treatment of HCV. For example,
changing the number of diagnosed patients to 75% fewer
than that modelled in the scenario (to 3,000 from 13,000
cases) increased the number of HCV-related HCCs and
liver-related deaths by 30%. Additionally, changing the
number of treated patients to 75% fewer than that
modelled in the scenario to 75% above that modelled
(3,000 to 21,000 cases) altered the number of HCV-related
HCCs from 90% above to 10% below the modelled0
HCV-related
decompensated cirrhosis
HCV-related HCC HCV-related liver
related deaths
860 410 390
(350 – 1630) (200–770) (170–700)
1280 880 740
(550 – 2150) (430 – 1510) (350 – 1140)
Table 5 Summary of the impact of each treatment scenario at 2020








HCV-related HCC HCV-related liver
related deaths
Base case 122000 107000 12600 1140 640 570
(80300 – 153000) (69900 – 138000) (5560 – 20600) (470 – 2050) (320 – 1180) (260–970)
Increasing diagnosis and
treatment
89400 83500 4850 410 310 280
(52300 – 122000) (48900 – 116000) (2050 – 10400) (160 – 980) (140 – 700) (120 – 600)
Figure 3 HCV-related morbidity and mortality from 2013 to 2020. The impact of increasing diagnosis and treatment of HCV compared to
the base-case scenario on the total number of infected cases (A), the number of patients with HCV-related fibrosis (B), HCV-related cirrhosis (C),
HCV-infected decompensated cirrhosis (D), HCV-related HCC (E) and the number of liver-related deaths caused by HCV (F) is illustrated. Sensitivity
analyses - the effect of different treatment options on HCV-related HCC and mortality.
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HCV changed from 95% above to 5% below respectively.
Sensitivity analysis showed that increasing treatment
numbers to 21,000 patients annually had a small impact on
the number of HCC cases and liver-related mortality in
2020 compared to the reductions already achieved in the
‘best case’ scenario. The number of treated patients
selected in the ‘best case’ scenario (11,710 by 2018) was
chosen to minimise the impact of morbidity and mortality.
However, further increases in treatment numbers would
have a large impact on the total number of infections in
England if eligibility is increased to patients with F0-F1
stage of fibrosis.
This analysis focused on chronically infected individuals.
Once a patient achieved SVR they were removed from the
infected cohort. Although studies have shown that patients
with SVR retain some risk of HCC, decompensation and
liver-related death, the rate of progression is substantially
lower than in patients with current infection [40].
Additionally, because patients achieving SVR are not
tracked, all re-infections in the model are handled as naïve
cases. Combined, these two limitations suggest that the
model may overestimate the impact that SVR has on HCV
liver-related morbidity and mortality. However, any
overestimate is likely to be limited. Firstly, the modelled
scenario aims to cure patients before they progress to
advanced disease, thus lowering the risk of disease
progression after cure. Secondly, the risk of HCV re-
infection is estimated to be small even in IDUs [41].
Furthermore, the analysis did not model healthcare or
treatment costs. Mean healthcare costs associated withTable 6 Sensitivity analyses - the effect of different treatmen




and treatment (Table 2)
– 310
Change segment treated Allow treatment of F1 400 (30%)
Restrict treatment to≥ F2 260 (−15%)
Change age of treated Allow treatment of 79+ 260 (−15%)
Restrict treatment to 69 400 (30%)
Change in the number treated
(current- 12,000 in 2018)
Treat 3,000 (75% fewer) 590 (90%)
Treat 6,000 (50% fewer) 470 (50%)
Treat 9,000 (25% fewer) 360 (15%)
Treat 15,000 (25% more) 300 (−5%)
Treat 18,000 (50% more) 290 (−5%)
Treat 21,000 (75% more) 280 (−10%)
Change in the number diagnosed
(Dx) (current- 13,000 in 2016)*
Dx 3,000 (75% fewer) 410 (30%)
Dx 7,000 (50% fewer) 350 (15%)
Dx 10,000 (25% fewer) 330 (5%)
*Increasing the diagnosis rate above 13,000 had no effect under the current treatmHCV increase as the disease progresses, underscoring
the importance of treating patients before they progress
to advanced disease [42]. Future analysis including costs
incurred by any service redesign to enable greater testing
and treatment, and indirect costs (e.g. loss of productivity)
or intangible costs (e.g. distress or pain) would be
beneficial. The analysis also assumes that there is immedi-
ate uptake of new therapies once they become available.
In reality, the uptake of treatment can be delayed as
new practice guidelines are developed and healthcare
professionals become used to new protocols and gain
clinical experience with new agents.
An additional limitation is that the increased mortality
rate was applied only to those estimated to be actively
injecting drugs between the ages of 15 and 44 years. Deaths
among active IDUs are usually due to non-HCV-related
factors, such as suicides, overdoses and accidents [34,43].
However, mortality due to IDU may persist after this age
due to, for example, HIV, hepatitis B, other addictions and
risk-taking behaviour. In addition, drug use may persist
after 44 years of age. However, this limitation means that
the model is likely to underestimate the benefits of
increasing HCV-treatment rates, for example, ex-IDUs
with HCV may not be known to services.
Maximising the potential reductions in HCV-related
mortality and morbidity associated with new treatments
and service structures means overcoming barriers to
care [14,16]. For example, we estimated that 49,730
viraemic individuals were living with a diagnosis of HCV
in 2013, equating to a viraemic diagnostic rate of 34.5%.
Therefore, most infected individuals are unaware of theirt options on HCV-related morbidity and mortality
CV-related
(percentage
scenario in Table 2)
Liver-related deaths caused by HCV in 2020















ent levels and so has not been included.
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approximately half were unaware of their status [4].
The diagnostic rate is less than the estimated rate in
Scotland, where approximately 52% of those with
chronic HCV infection were thought to have been
diagnosed [4]. The limited publicity of HCV testing and
minimal screening for HCV in high-risk groups in
England may account for the difference. For example,
a commitment to deliver ‘opt-out’ testing for blood-borne
viruses in prisons in England was agreed only in April
2014 [44].Conclusions
In conclusion, this analysis demonstrated that if
current HCV treatment practices in England continue,
the number of patients with HCV-related cirrhosis,
decompensated cirrhosis and HCC can be expected to rise
over the coming years. However, under a best-case
scenario improved treatment and diagnosis offer the
opportunity to halve HCV-related liver mortality and
HCV-related HCC by 2020. Realising these benefits in
England will probably require service redesign to remove
current barriers to care.
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